Table 1 Landmark overall survival rates.
From: Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study
Landmark OS (%, 95 CI) | MBC, total (n = 13,826) | MBC de novo (n = 2528) | MBC recurrent (n = 11,298) | MBC HR-positive (n = 10,497) | MBC HR-negative (n = 3,329) | MBC age of diagnosis, <50 years (n = 1777) | MBC age of diagnosis, 50–70 years (n = 6082) | MBC age of diagnosis, >70 years (n = 5967) |
|---|---|---|---|---|---|---|---|---|
2 years | 56 (55–57) | 56 (54–58) | 56 (49–55) | 63 (62–64) | 32 (31–34) | 68 (66–70) | 62 (61–63) | 46 (44–47) |
3 years | 45 (44–46) | 46 (44–48) | 45 (44–46) | 51 (50–52) | 25 (23–27) | 55 (53–58) | 51 (50–52) | 35 (34–36) |
5 years | 30 (29–31) | 31 (29–33) | 30 (29–31) | 34 (33–35) | 19 (17–20) | 40 (37–42) | 35 (34–36) | 22 (21–23) |
10 years | 14 (14–15) | 16 (14–18) | 14 (13–15) | 15 (14–16) | 12 (11–13) | 22 (20–25) | 18 (17–20) | 7 (7–9) |
